Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibody to CD23. Gomiliximab is a monoclonal antibody acting as an immunosuppressive drug for the treatment of allergic asthma. It targets the low affinity IgE receptor (FcεRII or CD23). The drug is a chimeric antibody from Macaca irus and Homo sapiens.
IgG1 - kappa
The details of the immunogen for this antibody are not available.
Suitable for use in WB, Neut, ELISA, IF, IP, FuncS, FC and most other immunological methods.
Tested positive against native human antigen.
Immunoglobulin G1, anti (human immunoglobulin E receptor type II) (human Macaca irus monoclonal IDEC 152 γ1 chain), disulfide with human Macaca irus monoclonal IDEC 152 kappachain, dimer
>95%, by SDS-PAGE with silver staining, under reducing conditions.
Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.
This receptor has essential roles in the regulation of IgE production and in the differentiation of B-cells (it is a B-cell-specific antigen).
IgE binding; binding; integrin binding; metal ion binding; receptor activity; sugar binding;
FCER2; Fc fragment of IgE, low affinity II, receptor for (CD23); CD23A, Fc fragment of IgE, low affinity II, receptor for (CD23A) , FCE2; low affinity immunoglobulin epsilon Fc receptor; CD23; CLEC4J; BLAST-2; CD23 antigen; fc-epsilon-RII; lymphocyte IgE receptor; immunoglobulin E-binding factor; C-type lectin domain family 4, member J; FCE2; CD23A; IGEBF;